Table 3.
N | OR% | mPFS (mo) | mOS (mo) | |
---|---|---|---|---|
Afatinib | ||||
LUX LUNG I trial 40 | ||||
Afatinib | 390 | 7 | 3.3 | 10.8 |
Placebo | 195 | <1 | 1.1 | 12.0 |
LUX LUNG IV trial 42 | 61 | 8.2 | 4.4 | 19 |
XL647 | ||||
Phase II trial52 | 41 | 3 | 3.6 | 16.1 |
<, less than.
N | OR% | mPFS (mo) | mOS (mo) | |
---|---|---|---|---|
Afatinib | ||||
LUX LUNG I trial 40 | ||||
Afatinib | 390 | 7 | 3.3 | 10.8 |
Placebo | 195 | <1 | 1.1 | 12.0 |
LUX LUNG IV trial 42 | 61 | 8.2 | 4.4 | 19 |
XL647 | ||||
Phase II trial52 | 41 | 3 | 3.6 | 16.1 |
<, less than.